167 related articles for article (PubMed ID: 32838941)
1. Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection.
Goodwin ML; Webster HS; Wang HY; Jenks JA; Nelson CS; Tu JJ; Mangold JF; Valencia S; Pollara J; Edwards W; McLellan JS; Wrapp D; Fu TM; Zhang N; Freed DC; Wang D; An Z; Permar SR
Virology; 2020 Sep; 548():182-191. PubMed ID: 32838941
[TBL] [Abstract][Full Text] [Related]
2. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
3. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.
Nelson CS; Huffman T; Jenks JA; Cisneros de la Rosa E; Xie G; Vandergrift N; Pass RF; Pollara J; Permar SR
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6267-6272. PubMed ID: 29712861
[TBL] [Abstract][Full Text] [Related]
4. IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Siddiqui S; Hackl S; Ghoddusi H; McIntosh MR; Gomes AC; Ho J; Reeves MB; McLean GR
Immunology; 2021 Mar; 162(3):314-327. PubMed ID: 33283275
[TBL] [Abstract][Full Text] [Related]
5. Identification of a neutralizing epitope within antigenic domain 5 of glycoprotein B of human cytomegalovirus.
Wiegers AK; Sticht H; Winkler TH; Britt WJ; Mach M
J Virol; 2015 Jan; 89(1):361-72. PubMed ID: 25320309
[TBL] [Abstract][Full Text] [Related]
6. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
[TBL] [Abstract][Full Text] [Related]
7. Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step.
Ye X; Su H; Wrapp D; Freed DC; Li F; Yuan Z; Tang A; Li L; Ku Z; Xiong W; Jaijyan D; Zhu H; Wang D; McLellan JS; Zhang N; Fu TM; An Z
PLoS Pathog; 2020 Aug; 16(8):e1008736. PubMed ID: 32745149
[TBL] [Abstract][Full Text] [Related]
8. A Novel Strain-Specific Neutralizing Epitope on Glycoprotein H of Human Cytomegalovirus.
Thomas M; Kropff B; Schneider A; Winkler TH; Görzer I; Sticht H; Britt WJ; Mach M; Reuter N
J Virol; 2021 Aug; 95(18):e0065721. PubMed ID: 34160252
[TBL] [Abstract][Full Text] [Related]
9. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
10. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Antibodies to Different Components of the Human Cytomegalovirus (HCMV) Pentamer gH/gL/pUL128L and Trimer gH/gL/gO as well as Antibodies Elicited during Primary HCMV Infection Prevent Epithelial Cell Syncytium Formation.
Gerna G; Percivalle E; Perez L; Lanzavecchia A; Lilleri D
J Virol; 2016 Jul; 90(14):6216-6223. PubMed ID: 27122579
[TBL] [Abstract][Full Text] [Related]
12. Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
Yamaguchi K; Shimizu H; Takahashi K; Nagatomo T; Nishimura T; Matsumoto M; Koshizuka T; Mori H; Inoue N; Torikai M
Vaccine; 2023 Jul; 41(31):4497-4507. PubMed ID: 37321896
[TBL] [Abstract][Full Text] [Related]
13. Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity.
Kirchmeier M; Fluckiger AC; Soare C; Bozic J; Ontsouka B; Ahmed T; Diress A; Pereira L; Schödel F; Plotkin S; Dalba C; Klatzmann D; Anderson DE
Clin Vaccine Immunol; 2014 Feb; 21(2):174-80. PubMed ID: 24334684
[TBL] [Abstract][Full Text] [Related]
14. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.
Pötzsch S; Spindler N; Wiegers AK; Fisch T; Rücker P; Sticht H; Grieb N; Baroti T; Weisel F; Stamminger T; Martin-Parras L; Mach M; Winkler TH
PLoS Pathog; 2011 Aug; 7(8):e1002172. PubMed ID: 21852946
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH/gL/pUL128-131 Pentameric Complex.
Ha S; Li F; Troutman MC; Freed DC; Tang A; Loughney JW; Wang D; Wang IM; Vlasak J; Nickle DC; Rustandi RR; Hamm M; DePhillips PA; Zhang N; McLellan JS; Zhu H; Adler SP; McVoy MA; An Z; Fu TM
J Virol; 2017 Apr; 91(7):. PubMed ID: 28077654
[TBL] [Abstract][Full Text] [Related]
16. Cell Fusion Induced by a Fusion-Active Form of Human Cytomegalovirus Glycoprotein B (gB) Is Inhibited by Antibodies Directed at Antigenic Domain 5 in the Ectodomain of gB.
Reuter N; Kropff B; Schneiderbanger JK; Alt M; Krawczyk A; Sinzger C; Winkler TH; Britt WJ; Mach M; Thomas M
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641474
[TBL] [Abstract][Full Text] [Related]
17. Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus.
Bootz A; Karbach A; Spindler J; Kropff B; Reuter N; Sticht H; Winkler TH; Britt WJ; Mach M
PLoS Pathog; 2017 Aug; 13(8):e1006601. PubMed ID: 28854233
[TBL] [Abstract][Full Text] [Related]
18. Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia.
Baraniak I; Kropff B; McLean GR; Pichon S; Piras-Douce F; Milne RSB; Smith C; Mach M; Griffiths PD; Reeves MB
J Infect Dis; 2018 May; 217(12):1907-1917. PubMed ID: 29528415
[TBL] [Abstract][Full Text] [Related]
19. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.
Freed DC; Tang Q; Tang A; Li F; He X; Huang Z; Meng W; Xia L; Finnefrock AC; Durr E; Espeseth AS; Casimiro DR; Zhang N; Shiver JW; Wang D; An Z; Fu TM
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):E4997-5005. PubMed ID: 24297878
[TBL] [Abstract][Full Text] [Related]
20. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
